×
Verastem Net Current Debt 2011-2025 | VSTM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Verastem net current debt from 2011 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
View More
Verastem Net Current Debt 2011-2025 | VSTM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Verastem net current debt from 2011 to 2025. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$217.3B
Amgen (AMGN)
$160.8B
Gilead Sciences (GILD)
$136.6B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$96B
CSL (CSLLY)
$78.5B
GSK (GSK)
$78.4B
Regeneron Pharmaceuticals (REGN)
$59.2B
Alnylam Pharmaceuticals (ALNY)
$42.1B
Argenex SE (ARGX)
$35.4B
BioNTech SE (BNTX)
$27B
Royalty Pharma (RPRX)
$20B
Insmed (INSM)
$19.8B
Biogen (BIIB)
$18.8B
Illumina (ILMN)
$15.3B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.4B
Moderna (MRNA)
$12.4B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Exact Sciences (EXAS)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.1B
Roivant Sciences (ROIV)
$7.8B
Regencell Bioscience Holdings (RGC)
$7.6B